Keytruda is an immunotherapy drug that is prescribed to cancer patients and is used to treat different types of cancer. It was first approved by the FDA in 2014 for the treatment of advanced or ...

Keytrida plus Lenvima improved survival and duration of response in patients with advanced hepatocellular carcinoma. Adding Keytruda (pembrolizumab) to Lenvima (lenvatinib) led to better duration of ...

Among the 27 responding patients, 81% had a duration of response (DOR) of six months or longer, and 37% had a DOR of 12 months or longer. In June 2020, KEYTRUDA was granted its first indication in ...

The FDA approved Keytruda for NSCLC based on several clinical trials. Keytruda was studied in people whose NSCLC had spread to other parts of the body (metastatic) and who had received no prior ...

Trodelvy plus Keytruda may maintain QOL and delay physical decline in PD-L1-positive mTNBC patients. The combination therapy showed improved progression-free survival and reduced symptom burden ...

Keytruda is a prescription drug that’s given as an intravenous (IV) infusion (and injection into a vein over a period of time). Learn about how the drug is given, how often you’ll receive doses, and ...

Dosage for Keytruda may vary based on the condition it’s being used to treat. The typical starting dose is 200 mg every 3 weeks or 400 mg every 6 weeks. Your doctor may adjust your dosage. The active ...

How Does Keytruda Work for RCC? Some cancer cells have what are called checkpoint proteins known as PD-L1 on their cell surface. Some immune cells in our bodies called T cells have proteins on their ...

After AstraZeneca’s Imfinzi last year claimed new territory in the biliary tract cancer space, Merck’s Keytruda has hit the scene with an FDA nod to match its rival. The approval in locally advanced ...

Keytruda, known scientifically as pembrolizumab, is an immunotherapy drug that has transformed cancer treatment for many patients worldwide. Traditional chemotherapy works by directly attacking the ...